Next Generation Nebulization Platform for Inhaled Macromolecular Therapeutics
Yeo LY, Rezk AR.
RDD Asia 2016. Volume , 2016: 25-32.
Abstract:
The advent of macromolecular drugs, notably in the last two decades, has heralded a revolution in therapeutics, with worldwide unit sales of biologics expected to constitute half of the top 100 selling drugs by 2018. The delivery of these macromolecules via inhalation is not only attractive as a non-invasive route that bypasses first-pass metabolic effects, but also allows local targeting in the treatment of pulmonary-related diseases. Nevertheless, inhaled administration of biologics is fraught with difficulties, not least due to their susceptibility to denaturation during aerosolization. Recently, it has been shown that a novel high frequency acoustomicrofluidic nebulization device is capable of overcoming these limitations. It preserves macromolecular integrity, which, together with its other advantages, including anticipated low manufacturing cost, miniaturizability, portability, and efficiency, render it a highly attractive platform for inhaled delivery of DNA, RNAi, peptide- and protein-based drugs and vaccines, and other next generation therapeutics.
I have a subscription
Log in for instant access.
I do not have a subscription
Purchase Article (in PDF format)
